Relationship between blood glucose control and improved cardiovascular outcome after stent implantation in diabetic patients

Cardiology

Volumn 116, Issue 1, 2010, Pages 48-50

  Raz, Itamar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; SULFONYLUREA;

ACUTE HEART INFARCTION; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; DIABETES CONTROL; DIABETES MELLITUS; DIET RESTRICTION; DRUG ELUTING STENT; DYSLIPIDEMIA; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RESTENOSIS; REVASCULARIZATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD GLUCOSE; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DRUG-ELUTING STENTS; HUMANS; HYPERGLYCEMIA; TREATMENT OUTCOME;

EID: 77951954254     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314330     Document Type: Note

References (18)

1. Ueda H, Mitsusada N, Harimoto K, Miyawaki M, Yasuga Y, Hiraoka H: Glycosylated hemoglobin is a predictor of major adverse cardiac events after drug-eluting stent implantation in patients with diabetes mellitus. Cardiology 2010;116:51-57.
2. Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG: Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 2006; 29: 26-31.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW: 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
4. Khaw KT, Wareham N, Luben R, et al: Glycated haemoglobin, diabetes and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001; 322: 15-18.
5. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
6. Dormandy JA, Charbonnel B, Eckland DJA, et al: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-1289.
7. Chiasson JL, Josse RG, Gomis R, et al: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072.
8. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, et al: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
9. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
10. Duckworth W, Abraira C, Moritz T, et al: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
11. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ: Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009; 32: 381-386.
12. The NAVIGATOR Study Group: Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med, E-pub ahead of print.
13. Currie CJ, Peters J, Tynan A, Evans M, Heine R, Bracco O, Zagar T, Poole C: Survival as a function of HBA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-489.
14. Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J: Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008; 155: 26-32.
15. Moses JW, Leon MB, Popma JJ, et al: Sirolimus- eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
16. Iijima R, Ndrepepa G, Mehilli J, et al: Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J 2007; 154: 688-693.
17. Corpus RA, George PB, House JA, et al: Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type 2 diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004; 43: 8-14.
18. Park DW, Flaherty JD, Davidson CJ, et al: Prognostic influence of diabetes mellitus on long-term clinical outcomes and stent thrombosis after drug-eluting stent implantation in Asian patients. Am J Cardiol 2009; 103: 646-652.